Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis b from a canadian public payer perspective

PharmacoEconomics

Volumn 29, Issue 12, 2011, Pages 1075-1091

  Dakin, Helen ^a,b   Sherman, Morris ^c   Fung, Scott ^c   Fidler, Carrie ^a   Bentley, Anthony ^a  

^a Decision Resources Group   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Adefovir; Antiretrovirals; Cost utility; Entecavir; Hepatitis B; Lamivudine; Tenofovir.

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CANADA; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EUROPE; FEMALE; FUNDING; HEALTH INSURANCE; HEPATITIS B; HEPATITIS B VIRUS; HIDDEN MARKOV MODEL; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADENINE; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CANADA; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; NATIONAL HEALTH PROGRAMS; PHOSPHONIC ACIDS; QUALITY-ADJUSTED LIFE YEARS; REVERSE TRANSCRIPTASE INHIBITORS; YOUNG ADULT;

EID: 81255176940     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11589260-000000000-00000     Document Type: Article

References (72)

1. WHO. Fact sheet no. 204: hepatitis B. Geneva: WHO, 2008 Aug [online]. Available from URL: http://www.who.int/ mediacentre/factsheets/fs204/en/ [Accessed 2011 Sep 7]
2. Wright TL. Introduction to chronic hepatitis B infection. Am J Gastroenterol 2006; 101 Suppl. 1: S1-6 (Pubitemid 43381694)
3. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol 2007; 21 Suppl. C: 5-24C
4. Hoffmann-La Roche Limited. Product monograph: pegasys peginterferon alfa-2a injection (pre-filled syringes: 180 mcg/0.5 mL, single use vials 180 mcg/1 mL) [online]. Available from URL: http://www.rochecanada.com/gear/ glossary/servlet/staticfilesServlet?type=data&communityId =re753001&id=static/attachedfile/re7300002/re77300002/AttachedFile-08765. pdf [Accessed 2011 Sep 7]
5. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17 (Pubitemid 39296307)
6. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alphainterferon treatment in patients with hepatitis B e antigenpositive chronic hepatitis B: A meta-analysis. Ann. Intern. Med. 1993; 119: 312-23 (Pubitemid 23319890)
7. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42
8. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96 (Pubitemid 36337972)
9. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22 (Pubitemid 37500436)
10. Snow-Lampart A, Chappell B, Curtis M, et al. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomised to receive tenofovir DF 300 mg QD [poster]. The 59th Annual Meeting of the American Association for the Study of Liver Disease; 2008 Oct 31-Nov 4; San Francisco (CA)
11. Khungar V, Han SH. A systematic review of side effects of nucleoside and nucleotide drugs used for treatment of chronic hepatitis B. Curr Hepat Rep 2010; 9: 75-90
12. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-14
13. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51 (Pubitemid 44958517)
14. Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos (t)ides for treatment of chronic hepatitis B. Value Health 2010; 13 (8): 934-45
15. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10 (Pubitemid 43357804)
16. National Institute for Health and Clinical Excellence. Bristol- Myers Squibb Pharmaceuticals Ltd. Entecavir (baraclude) for the treatment of chronic hepatitis B single technology appraisal submission to the National Institute forHealth and Clinical Excellence. London: NICE, 2007 Nov
17. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Eng J Med 2008; 359: 2442-55
18. Ontario Drug Benefit. eFormulary. Prices effective 2008 Aug 28 [online]. Available from URL: https://www.health info.moh.gov.on.ca/formulary/index.jsp [Accessed 2008 Sep 17]
19. RAMQ formulary. 17th ed. 2008 Jun 2 [online]. Available from URL: https://www.prod.ramq.gouv.qc.ca/DPI/PO/ Commun/PDF/Liste-Med/Liste-Med/liste- med-2008-06-02-en.pdf [Accessed 2011 Sep 6]
20. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: A systematic review and Bayesian metaanalyses. Gastroenterology 2010; 139: 1218-29
21. Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health 2010 Dec; 13 (8): 922-33
22. Buti M, Brosa M, Casado MA, et al. Modeling the costeffectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009; 51 (4): 640-6
23. Deniz B, Buti M, Brosa M, et al. Cost-effectiveness simulation analysis of tenofovir disoproxil fumarate (tenofovir), lamivudine, adefovir dipivoxil (adefovir) and entecavir of HBeAg negative (-) patients with chronic hepatitis-B (CHB) in Spain [abstract 557]. J Hepatol 2008; 48 Suppl. 2: S209
24. Deniz B, Everhard F. Cost-effectiveness simulation analysis of tenofovir disoproxil fumarate (tenofovir) in HBeAg negative (-) patients with chronic hepatitis-B (CHB) in Italy and France [abstract 559]. J Hepatol 2008; 48 Suppl. 2: S210
25. Product monograph: hepsera- adefovir dipivoxil tablets (10 mg). Antiviral agent. Date of revision: 2009 May 25. Foster City (CA): Gilead Sciences, Inc. [online]. Available from URL: http://www.gilead.ca/pdf/ca/hepsera-pm- english.pdf [Accessed 2010 Jun 17]
26. Baraclude- (entecavir) tablets 0.5 mg, oral solution 0.05 mg/mL. Antiviral: product monograph. Bristol-Myers Squibb Canada [online]. Available from URL: http:// www.bmscanada.ca/static/products/en/pm-pdf/Baraclude-E- 19%20Nov%202010-PM-DIST-CLN.pdf [Accessed 2011 Sep 6]
27. Viread- (tenofovir disoproxil fumarate tablets) 300 mg antiretroviral agent: product monograph. Gilead Sciences, Inc. [online]. Available from URL: http://www.gilead.ca/ pdf/ca/viread-pm-english.pdf [Accessed 2011 Sep 6]
28. Canadian Coordinating Office for Health Technology Assessment. CEDAC final recommendation on reconsideration and reasons for recommendation: tenofovir (Viread- -Gilead Sciences Canda, Inc.) 2006 Mar 15 [online]. Availablefrom URL: http://www.cadth.ca/media/cdr/complete/cdr-complete-Viread- Resubmission-march2006.pdf [Accessed 2011 Sep 6]
29. Canadian Agency for Drugs and Technologies in Health. CEDAC final recommendation and reasons for recommendation: tenofovir/emtricitabine/efavirenz (Atripla- Bristol-Myers Squibb Canada andGilead Sciences Canada, Inc.) 2008 Apr 17 [online]. Available from URL: http://www.cadth.ca/media/cdr/complete/cdr- complete-Atripla-April-17-2008.pdf [Accessed 2011 Sep 6]
30. Fung SK, Wong FS, Wong DK, et al. Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center. Liver Int 2006; 26: 796-804 (Pubitemid 44165247)
31. Gagnon YM, Levy AR, Iloeje UH, et al. Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. J Clin Gastroenterol 2004; 38: S179-86
32. Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: A multinational study of utilities from infected and uninfected persons. Value Health 2008; 11: 527-38 (Pubitemid 351712982)
33. de FranchisR,Hadengue A, LauG, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003; 39 Suppl. 1: S3-25
34. Fung SK, Mazzulli T, El-Kashab M, et al. Lamivudineresistant mutation detected among treatment-naive hepatitis B patients is common and may be associated with treatment failure [poster]. 59th Annual meeting of the American Association for the Study of Liver Disease; 2008 Oct 31-Nov 4; San Francisco (CA)
35. Statistics Canada. Table 102-0218: life expectancy, abridged life table, by age group and sex, three-year average, Canada, provinces, territories, health regions and peer groups, occasional (years) [online]. Available from URL: http:// www5.statcan.gc.ca/cansim/a05?id=1020218&pattern= Life+expectancy%2C+abridged+life+table&stByVal=1& paSer=&lang=eng [Accessed 2011 Sep 6]
36. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd edition. Ottawa (ON): CADTH, 2006 [online]. Available from URL: http://www.cadth.ca/media/ pdf/186-EconomicGuidelines-e.pdf [Accessed 2011 Sep 6]
37. Canadian Agency for Drugs and Technologies in Health. CEDAC final recommendation on reconsideration and reasons for recommendation: telbivudine (Sebivo treadmark; - Novartis Pharmaceuticals Canada Inc.) 2007 Sep 26 [online]. Available from URL: http://www.cadth.ca/media/cdr/complete/cdr-complete-Sebivo- September-26-2007.pdf [Accessed 2011 Sep 6]
38. Canadian Agency for Drugs and Technologies in Health. CEDAC final recommendation on reconsideration and reasons for recommendation: Entecavir (baraclude treadmark; - Bristol- Myers Squibb Canada). 2007 Nov 28 [online]. Available from URL:http://www.cadth.ca/media/cdr/complete/cdr-complete-Baracude- November-28-2007.pdf [Accessed 2011 Sep 6]
39. Gilead Sciences. Study GS-US-174-0106 week 48 clinical study report: tenofovir disoproxil fumarate (DF and emtricitabine/ tenofovir DF fixed-dose combination). Data on file, 2008
40. Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010; 139: 1207-17
41. van Bommel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318-25 (Pubitemid 44214870)
42. Buti M, Hadziyannis S, Mathurin P, et al. Tenofovir disoproxil fumarate (TDF) is highly active for treatment of chronic hepatitis B in subjects with cirrhosis [podium presentation #1352]. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
43. Crowley S, Tognarini D, Desmond P, et al. Introduction of lamivudine for the treatment of chronic hepatitis B: Expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 2002; 17: 153-64 (Pubitemid 34415668)
44. Crowley SJ, Tognarini D, Desmond PV, et al. Costeffectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000; 17 (5): 409-27 (Pubitemid 30398801)
45. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294-8
46. Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology 1988; 8: 493-6
47. Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008; 48: 728-35
48. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-36 (Pubitemid 41096641)
49. Heathcote J, George J, Gordon S, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103). 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
50. Reijnders JG, Pas SD, Schutten M, et al. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 2009; 50: 674-83
51. Kind P. Hardman G. Macran S., UK population norms for EQ-5D York: Centre for Health Economics 1999 Nov.
52. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. York: Centre for Health Economics, 1999 Nov 52. Wong JB, Koff RS, Tine F, et al. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann. Intern. Med. 1995; 122: 664-75
53. Statistics Canada. Table 326-0021. Consumer price index (CPI), 2005 basket, annual (2002=100 unless otherwise noted), CANSIMdatabase. Based on Canadian geographical region and healthcare commodity group [online]. Available from URL: http://www5.statcan.gc.ca/cansim/pick-choisir? lang= eng&searchTypeByValue=1&id=3260021 [Accessed 2011 Sep 6]
54. Zethraeus N, Johannesson M, Jonsson B, et al. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies. Pharmacoeconomics 2003; 21 (1): 39-48 (Pubitemid 36078491)
55. Stinnett AA, Mullahy J. Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18: S68-80 (Pubitemid 28175944)
56. McGuire A. Chapter 1: Theoretical concepts in the economic evaluation of health care. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001
57. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 479-500 (Pubitemid 30398806)
58. Briggs AH, Goeree R, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002; 22: 290-308 (Pubitemid 34791317)
59. Claxton K. The irrelevance of inference: A decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18: 341-64 (Pubitemid 29242816)
60. Kamal A, Gerson L, Ahmed A. Cost-effectiveness of new treatment paradigms for e-Ag negative chronic hepatitis B [abstract no. 987]. 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2007 Nov 2-6; Boston (MA)
61. Kanwal F, Gralnek IM, Martin P, et al. Treatment alternatives for chronic hepatitis B virus infection: A costeffectiveness analysis. Ann. Intern. Med. 2005; 142: 821-31 (Pubitemid 40664041)
62. Shepherd J, Jones J, Takeda A, et al. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: A systematic review and economic evaluation. Health Technol Assess 2006; 10: iii-iv, xi-xiv, 1-183
63. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88 (Pubitemid 350294224)
64. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical Publications, 1997
65. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008 Jun [online]. Available from URL: http://www.nice. org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008. pdf [Accessed 2010 Jun 17]
66. Minuk G, Uhanova J. Chronic hepatitis B infection in Canada. Can J Infect Dis 2001; 12: 351-6
67. Gish RG, Gadano AC. Chronic hepatitis B: current ep demiology in the Americas and implications formanagement. J Viral Hepat 2006; 13: 787-98 (Pubitemid 44748283)
68. Zhang J, Zou S, Giulivi A. Epidemiology of hepatitis B in Canada. Can J Infect Dis 2001; 12: 345-50 (Pubitemid 34169239)
69. Yang H, Qi X, Sabogal A, et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10: 625-33 (Pubitemid 41224954)
70. Novartis Pharmaceuticals Canada Inc. Prescribing information: Sebivo- (telbivudine). Tablets (film-coated) 600 mg. Antiviral agent. Dorval (QC): Novartis Pharmaceuticals Canada Inc., 2006 [online]. Available from URL: http://www.sebivo.com.ua/files/sebivo-scrip-e.pdf [Accessed 2008 Apr 30]
71. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naïve and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 1185-92 (Pubitemid 38457242)
72. Curtis M, Harris J, Borroto Esoda K, et al. Tenofovir is equally active in vitro against wild-type HBV clinical isolates of genotypes A-H [abstract]. Hepatology 2008; 48: 735A